Study of Adjuvant ONO-4538 With Resected Gastric Cancer
The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.
Gastric Cancer
DRUG: Nivolumab|DRUG: Tegafur-gimeracil-oteracil potassium|DRUG: Oxaliplatin|DRUG: Capecitabine|DRUG: Placebo
Relapse-free survival (RFS), 5 years
Overall survival (OS), 5 years|3-year OS rate, 3 years|5-year OS rate, 5 years|3-year RFS rate, 3 years|5-year RFS rate, 5 years|Safety will be analyzed through the incidence of adverse events, serious adverse events, Up to 28 days from last dose|Safety will be analyzed through the incidence of laboratory abnormalities, Up to 28 days from last dose
The purpose of study is to evaluate the efficacy and safety of postoperative adjuvant chemotherapy with Nivolumab in combination with tegafur-gimeracil-oteracil potassium (S-1 therapy) or capecitabine + oxaliplatin (CapeOX therapy), in comparison with placebo in combination with S-1 therapy or CapeOX therapy, in pStage III gastric cancer (including esophagogastric junction cancer) after D2 or more extensive lymph node dissection.